Th is article examines recent developments in EU governance of organ donation and transplantation, focusing on an analysis of the Commission's action plan and the proposed Directive. While the aims of the plan are laudable, a number of concerns remain with respect to the timetable for the plan and the adoption of the Directive, as well as the management of ethical and risk issues. In the fi nal analysis, the added value of EU governance initiatives in the fi eld is likely to be measured by the extent to which they successfully address the ongoing problem of organ shortage in Member States.
Introduction
Th ere has been an increasing level of policy activity at EU level in recent years in the fi eld of organ donation and transplantation. In December 2008, the European Commission (Commission) published a six-year action plan and argued for the added value of EU action on a number of grounds, including the likelihood of an increase in the rate of organ donation through the sharing of best practices, best models and expertise; the creation of an EU-wide risk regulation regime which would establish basic quality and safety requirements in organ donation and transplantation, as well as reduce risks posed to donors and recipients; and increased cross-border exchange of organs, which was likely to be of particular benefi t for smaller Member States with limited donor pools, as well as for difficult-to-treat or urgent patients.
1 Th e Commission identifi ed three main challenges in its action plan: increasing organ availability; enhancing the effi ciency and accessibility of transplantation systems; and improving the quality and safety of organs for transplant. Ten priority actions were identifi ed in order to address these challenges. 2 Accompanying the publication of the action plan by the Commission was a proposal for a framework Directive which would establish a risk regulation regime in relation to human organs intended for transplantation (proposed Organs Directive).
3 Th e EU's power to take action in the fi eld of organ donation and transplantation is derived from the public health competence set out in Article 168 TFEU (ex Article 152 EC). Th ere are a number of components to action that may be taken at EU level under this Article, which is based on shared competence with Member States in relation to 'common safety concerns in public health matters'. 4 First, emphasis is placed on encouraging cooperation between Member States in the areas referred to in the Article and, if necessary, to lend support to their action. Th is specifi cally includes encouraging cooperation to improve 'the complementarity of health services in cross-border areas'. In this regard, the Commission may 'in close contact' with the Member States take any useful initiative to promote such coordination, in particular initiatives aimed at the establishment of guidelines, indicators, the organisation of exchange of best practice, and the preparation of the necessary elements for periodic monitoring and evaluation'. 5 Second, the European Parliament and Council are empowered to adopt 'measures setting high standards of quality and safety of organs', although 'these measures shall not prevent any Member State from maintaining or introducing more stringent protective measures'. 6 Finally, it is emphasised that any measures so adopted 'shall not aff ect national provisions on the donation or medical use of organs.' 7 Th e aim of this article is to examine recent developments in EU governance of organ donation and transplantation, focusing on an analysis of the Commission's current action plan and the proposed Organs Directive. While the aims of the plan are laudable, I argue that a number of concerns remain with respect to the timetable for achieving its objectives, as well as the management of ethical and risk issues. Nevertheless, it should be seen as a welcome development, particularly if it results in increasing organ availability in Member States. A further issue regarding timing is raised by the publication of the proposed Organs Directive. Given the ambitious objectives set out in the plan, the diff ering levels of infrastructural development of organ procurement and transplantation, and limited national administrative and personnel resources, I question whether it may be more appropriate to focus in the short term on action that is most likely to bring about effi cient and eff ective organ procurement at national level. Th e adoption of an Organs Directive could then be re-considered at regular intervals as an option in the medium to long term. In order to consider these questions in more detail, the Commission's action plan is examined in detail in the fi rst section of the paper. Th ereafter, key aspects of the proposed Organs Directive are analysed. Th e fi nal section examines a number of concerns regarding the use of expertise, as well as the management of ethical and risk issues, that require further consideration in the context of adding value to EU governance in the fi eld.
Emerging EU Governance on Organ Donation and Transplantation

Early Initiatives
A treaty competence to adopt minimum harmonisation measures setting standards for quality and safety in relation to blood, tissue and organs was created through the Treaty of Amsterdam which came into force in 1999. 8 Th is subsequently led to a series of governance initiatives which resulted in the adoption of the Blood Directive in January 2003 9 and the Tissues and Cells Directive in 2004. 10 It was acknowledged by the Commission at an early stage, however, that a diff erent approach was required in the case of organ donation and transplantation to that of blood and tissues/cells. Th is was attributable primarily to the differential risk-benefi t analysis that was required in the fi eld, against a background of persisting organ shortage at national level.
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A series of EU-sponsored conferences were organised to examine issues involving organ donation and transplantation between 2000 and 2003. 12 In 2003, a strong political impetus was provided for further work in the fi eld, with the Greek Presidency identifying the need to combat organ traffi cking as a priority. Subsequently, the Italian Presidency convened an expert conference to discuss quality and safety issues in organ donation and transplantation. Th e conclusions from the conference described organ shortage and organ traffi cking as the main priorities in the fi eld and underlined the fact that quality and safety aspects needed to be situated within a framework which took account of supply and demand issues involving organs. 13 Various empirical and scientifi c research projects were subsequently commissioned and an extended consultation process was conducted by the Commission with relevant experts and stakeholders to identify areas of concern, as well as levels of support for various policy options.
Th e Commission's Communication of May 2007
Following the response received to its initial consultation process, the Commission published an initial Communication in May 2007 setting out a proposed action plan in the fi eld.
14 Th is was accompanied by an Impact Assessment which provided a detailed explanation, as well as rationales, for its plan.
15 Th e Commission stated in this initial action plan that it intended to focus on strengthening cooperation between Member States and identifi ed what it considered to be the main challenges in organ donation and transplantation within the EU. It confi rmed that it intended to draw on the Open Method of Coordination (OMC) in order to identify common objectives for which it was agreed an EU response was needed; to develop both qualitative and quantitative indicators from which benchmarking could be undertaken; and to facilitate the sharing of relevant information on a regular basis in order to foster best practice in areas where this had been identifi ed as necessary. Such areas included organisational models for organ donation, procurement and exchange, the promotion of an EU donor card, and access to Member State transplant facilities by non EU-citizens. Although organ traffi cking was acknowledged to be a matter that warranted further consideration, it was not identifi ed as a priority action. 16 Th e feedback from the European Parliament (Parliament) and the Council on the Commission's initial action plan was largely positive. Th e Council emphasised, however, that the Commission needed to work closely with Member States and to proceed on the basis of 'agreed objectives and priorities'. 17 In addition, the Parliament emphasised that the Commission should ensure that the implementa- tion of the action plan would not create 'an additional administrative burden for Member States or service providers', or would otherwise result in requirements that could result in a decrease in the number of potential or actual donors'.
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Th e feedback received from national experts and stakeholders was also broadly supportive in principle. 19 Concern was expressed by a number of experts, however, about the use of OMC to implement the action plan, on the grounds that it was likely to contribute to an unwanted administrative burden at national level. It was suggested that if OMC was to be used, then it needed to be specifi cally tailored to the fi eld, as well as being highly fl exible. 20 Despite the concerns expressed by experts, its use is supported by both the Commission as well as under Article 168(2) TFEU. Th e use of OMC has grown in popularity across a range of policy sectors since its endorsement by the European Council at the Lisbon Summit of 2000. It is said to permit a more fl exible and participatory approach to the formation of policy, and contrasts with the traditional command and control models which have been more commonly employed at EU level.
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Evidence of its growing infl uence in EU policy-making processes is revealed in the Commission's active promotion of the methodology for developing organ donation and transplantation policy, and it marks a clear change in approach from that taken in relation to earlier governance initiatives involving blood and tissues/cells. 22 Although it is early days yet, it remains to be seen how eff ective Notwithstanding its growing institutional popularity at EU level, there has been much academic debate about the eff ectiveness of OMC processes. Th ere is little published empirical research to substantiate its eff ectiveness in either engendering consensus in a given policy area at EU level, or in facilitating horizontal or vertical policy transfer or organisational learning. Concerns have also been raised about the extent to which OMC actually facilitates greater participation in EU decision-making processes in practice. Participation requires being able to access and respond to Commission working documents, background knowledge in relation to issues under discussion, and being able to be physically present at meetings which are regularly held in Brussels. Th is limits the fi eld of potential participants in a given policy area, and the evidence available to date is that the promise of OMC as an instrument for enhancing participatory governance at EU level has not been realised (see J. Zeitlin, "Social Europe and Experimentalist Governance: Towards a New Constitutional Compromise" in G. OMC will be in terms of strengthening cooperation and coordination across Member States in organ donation and transplantation policy. Th e danger remains that using OMC may add a signifi cant administrative burden at national level, notwithstanding the Commission's claims to the contrary.
Th e EU's Action Plan on Organ Donation and Transplantation (2009-2015)
Taking on board institutional, stakeholder and expert feedback, the Commission published a further Communication and Impact Assessment in December 2008, as well as a proposal for a framework Directive. Th is Communication set out a revised and more detailed action plan. It confi rmed that increasing organ availability, enhancing the effi ciency and accessibility of transplantation systems and improving the quality and safety of organs for transplant remained the main challenges to be addressed at EU level and ten priority actions were identifi ed in order to address such challenges. It also confi rmed that such priority actions would be addressed in the context of pursuing strengthened cooperation between Member States. Th e OMC methodology would be used to facilitate the identifi cation and development of common objectives and guidelines, jointly agreed indicators and benchmarks, regular reporting, and identifi cation and sharing of best practices. Th e Commission emphasised that it was a matter for Member States how best to achieve these objectives. 23 In the following sections, I identify key issues which have emerged from the Commission's current action plan.
Increasing Organ Availability
Priority Actions 1 to 5 in the Commission's current action plan aim to address the challenge of increasing organ availability throughout the EU, focusing in particular on increasing rates of deceased organ donation at national level.
24 Th e importance accorded to increasing organ availability refl ects the fact that the ongoing shortage of organs remains the key issue structuring governance initiatives in the fi eld, with more than 56,000 patients on waiting lists within the EU, with many dying while waiting for a suitable organ to become available. 25 Priority Action 1 focuses on the need to appoint transplant donor coordinators (TDCs) in every hospital where there is potential for organ donation. Th is is in addition to devel- oping internationally-recognised standards, eff ective training and international accreditation for TDCs.
Th e appointment of TDCs in every hospital where organ donation is an option has been identifi ed as a key element in increasing the rate of (deceased) organ donation at national level. Spain enjoys the highest rate of deceased organ donation in the EU (see Table 2 ), and much of its success has been attributed to the use of TDCs who are predominantly physicians, with specialities in nephrology or intensive care. Th ey do not report to transplant teams, but rather to the hospital that employs them, in addition to regional and national transplant organisations. Th ey are provided with ongoing and intensive training in all aspects of organ donation and transplantation activity and their work is seen as making the diff erence between success and failure with respect to increasing the rate of (deceased) organ donation. 26 In other Member States, such as the UK, TDCs are employed by, and therefore answerable to, local hospitals. It was recognised that insuffi cient systemic or logistical support was provided to them, thus hampering their ability to identify potential opportunities for organ donation. Drawing inspiration from the Spanish model, reforms are currently being implemented which recognise their importance to the success of the national organ procurement programme.
27 Support for this type of reform will no doubt be reinforced through the EU's action plan.
Th e need to promote quality improvement programmes in every hospital where there is potential for organ donation is identifi ed in Priority Action 2 as key to realising the objective of increasing organ availability. Th is action draws on a previously-adopted Recommendation by the Council of Europe in this area, 28 and is designed to promote a self-evaluation process of organ donation operating in the context of national health systems, which is to be jointly performed by specialists in intensive care and TDCs in every hospital where there exists a potential for organ donation. Th e aim of the evaluation process is to identify best practices across Member States, which would then inform the design and implementation of appropriate methodologies for quality improvement programmes.
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Th e promotion of living organ donation programmes has been identifi ed as Priority Action 3. In developing such programmes, the focus is on promoting altruistic donation, the development of best practices, and the creation of national registries to hold data on living organ donors. Living organ donation currently represents 17% of kidney transplant activity in Europe and includes the donation 26) R. Matesanz, and B. Dominguez-Gil, "Strategies to optimize deceased organ donation", Transplantation Reviews 21 (2007) of kidneys, lobes of lungs, as well as portions of the liver, pancreas and intestines. Th e extent to which reliance is placed on this form of donation varies widely, however, with a very low rate in Spain of 2 transplants per million population (pmp) to a rate of 20.7 pmp in countries such as Norway. 30 In identifying this area as a priority action, the Commission has recognised that there is a need to gather data on the medical, psychological, fi nancial and social consequences following on from donation of organs by living donors, as well as to record any risk factors or other health problems experienced by living organ donors posttransplant.
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What the action plan does not formally acknowledge in prioritising this area of organ donation and transplantation is the signifi cant degree of debate in relevant expert and policy communities over the merits (or otherwise) of living organ donation. It has been argued that living organ donation programmes should be promoted as a successful way of addressing the chronic shortage of organs available for transplantation, which is not currently addressed by deceased organ donation. As such, it should be promoted in line with agreed medico-scientifi c guidelines and/or regulatory frameworks. Th e adoption of this approach in North America has seen a substantial increase in the rate of living organ donation over the last ten to fi fteen years, with transplant teams accepting donations from both genetically-related and non-genetically related donors, provided that there is informed consent and no material gain from the process of organ donation. 32 In the case of Member States such as the UK, for example, a national regulatory authority oversees cases of living organ donation and transplantation in line with framework legislation and more detailed guidelines provided in a supporting code of practice.
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For others, living organ donation raises troubling ethical and human rights' issues. It has therefore been argued that if living organ donation is to be permitted at all, then it should be limited to those with a genetic or spousal relationship with the potential organ recipient, so as not to off end the principle against the instrumentalisation of human beings, whether for fi nancial gain or some other comparable advantage. 34 In addition, concerns have been raised about whether the rise in living organ donation will undermine eff orts to increase deceased organ donation. Th e latter form of donation represents no risk to the donor, whereas the same cannot be said for living organ donors, as there are recognised risks of complications and/or death arising from the procedure. 35 Finally, ethical concerns have been raised about the fact that organ donation by a living donor involves the performance of risky medical procedure, which is of no direct therapeutic benefi t to the individual in question. 36 It is to be hoped that the Commission ensures that account is taken of such ethical concerns in undertaking work on promoting living organ donation programmes.
Priority Action 4 focuses on the need to improve the knowledge and communication skills of health professionals and patient support groups on organ transplantation in seeking to increase organ availability. Specifi c activities to be taken in relation to this priority action include developing strategies to make better use of mass media and improve public education about organ donation and transplantation. Th is would involve ensuring that there is a systematic and comprehensive approach to the dissemination of information about organ donation and transplantation through media outlets, and would include regular meetings with journalists and national opinion leaders. In this regard, a systematic media campaign of this kind in Spain was found to have created a positive societal atmosphere around supporting organ donation and transplantation. 37 In a Eurobarometer survey conducted in 2006 on the issue of organ donation, it was found that 41% of those polled stated that they had discussed the matter with their family, although there was a wide variation between countries ranging from 75% in the Netherlands to 24% in Austria. One of the conclusions from the survey was that public education about the processes of organ donation and transplantation was very important in terms of promoting organ donation after death.
38 Th e fi ndings from the Eurobarometer survey, however, do not correlate well with the rate of family refusals to consent to organ donation in relation to a deceased family member (see Table 1 ). It has been suggested that while there may be broad public support in principle for deceased organ donation, the reality of dealing with organ donation during a time of great emotional distress and bereavement makes decision-making for families much more diffi cult. Research has shown that at such time, families become concerned about how and in what circumstances the diagnosis of death is made, as well as seeking to protect the body of their deceased family member from being dissected or otherwise 'cut up'. In many cases this accounts for families' refusals to permit organ donation, notwithstanding the fact that the deceased family member may have held positive views about organ donation during her or his lifetime. 39 Th is means that simply suggesting that more and better public education about organ donation and transplantation on its own will not necessarily lead to higher rates of organ donation, and therefore a more nuanced and diff erentiated approach to the delivery of public education is needed. 
Enhancing the Effi ciency and Accessibility of Transplant Systems
Enhancing the effi ciency of national transplant systems through implementing optimal organisational structures and other arrangements is seen as a key factor in meeting the challenge of increasing organ availability. Drawing on a range of data and research sources, the Commission has identifi ed signifi cant variation in rates of organ donation and transplantation activity in Member States, concluding that certain organisational models performed better than others in terms of increasing organ availability. Priority Actions 6 to 9 in the current action plan are therefore focused on 'identifying the most effi cient systems, sharing experiences and promoting best practices in the area'. 41 Priority Action 6 is specifi cally focused on enhancing national organisational models of organ donation and transplantation. Th is will require Member States to develop their own national priority actions in relation to improving their national and/or local organisational models. Th is will then provide a basis for subsequent evaluation and improvement, which will be facilitated through peer review at EU level. Consideration will also be given to making use of EU structural funds to assist in the development of national transplant systems in specifi c Member States where this may be necessary, as well as promoting networks of centres of reference on best practices. 42 In terms of work that has already been done in relation to enhancing the efficiency of transplant systems, the Commission will be able to draw on the work that has already been undertaken by the Council of Europe on this issue. Th e Council of Europe has long been active in the fi eld of organ donation and transplantation, having established an expert advisory committee; 43 adopted resolutions and recommendations on various ethical and policy issues; 44 developed and updated quality and safety standards; 45 and published annual statistical data on organ donation and transplantation activity in its Member States. 46 Its expert advisory committee recently published a European consensus document covering how best to enhance the effi ciency of national transplant systems with a review to 41 improving rates of organ donation. 47 Such document relies to a great degree on what has become known as the Spanish model of organ procurement, which has resulted in Spain achieving the highest rate of deceased organ donation in Europe (see Table 2 ).
Key features of the model include the establishment of a transplant coordination network which operates at local, regional and national levels; continuous audits of potential organ donation opportunities through brain deaths and donation through intensive care units; a central administrative agency that coordinates and supports all the processes of organ donation; ongoing training of healthcare professionals involved in all aspects of organ donation and transplantation; the establishment of a reimbursement system for hospitals engaged in organ procurement; and the design and implementation of media and education campaigns to present information and a positive approach to organ donation.
48 Th e Spanish model has provided the basis for the adoption of more effi cient systems of organ procurement in Tuscany, Italy, as well as in several countries in Latin America.
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It has also recently been the subject of detailed study by UK policy-makers who have identifi ed enhanced effi ciency resulting in higher rates of organ donation as being associated with the implementation of optimum organisational arrangements for organ procurement. 50 Th e need to establish commonly-agreed rules and structures to promote greater cross-border exchange of organs between Member States is identifi ed as Priority Action 8. A number of cross-border organ exchange organisations already exist within Europe, including Eurotransplant, Scandiatransplant and Balttransplant. Eurotransplant is responsible for the mediation and allocation of organ donation procedures in Austria, Belgium, Germany, Luxembourg, the Netherlands and Slovenia. Participants in this supranational organisation include hospitals specialising in organ donation and transplantation, as well as tissue-typing laboratories. on work already being done by these regional organisations, the Commission has identifi ed that there is signifi cant potential for the rate of cross-border exchange to be increased, off ering greater scope for diffi cult-to-treat and urgent patients, as well as ensuring effi cient distribution of any surplus organs in a particular Member State. What is surprising about the Commission's approach to this issue is that there has been little in the way of acknowledgement, let alone detailed examination, of the broader issues that should be taken into account in determining what should constitute just and fair criteria for the allocation and/or exchange of organs on an EU-wide basis in relation to all patients, not just the specifi c categories identifi ed by the Commission. Allocation criteria for organs are clearly applied at national level, as well as through existing regional organ exchange organisations. In terms of work to be done in relation to this priority action, it is important that the Commission ensures that just, fair and transparent criteria and procedural requirements are in place with regard to cross-border allocation of organs.
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In the wake of feedback received from consultations with national experts, the Commission has also recognised the importance of promoting EU-wide agreements on important areas of transplantation medicine under Priority Action 7. Th ese include patient mobility for treatment within the EU; the treatment of patients from outside the EU; the monitoring of organ traffi cking; and agreed priorities and strategies for future research programmes. 54 Although the issue of organ traffi cking is not specifi cally identifi ed as a priority action by the Commission in its action plan, it has underlined the importance of developing a common approach between Member States in relation to dealing with the problem. Notwithstanding concerns expressed by experts, stakeholders and EU institutions, one of the problems that the Commission has experienced to date has been in gathering data on the nature and extent of the problem of organ traffi cking in the EU context.
In recent years, the Council of Europe has taken the lead in this regard, publishing a report and adopting a recommendation on ethical and legal issues raised by 'transplant tourism' and organ traffi cking. 55 It also endorsed the Declaration of Istanbul adopted at an international summit held in 2008, which condemns unethical activities facilitated by organ traffi cking whilst at the same time acknowledging that strategies which increase organ availability to meet growing demand off ers the best way forward for dealing with the problem. 56 It remains to be seen In relation to promoting EU-wide agreements on a range of issues involving transplant medicine, the Commission will be able to draw on the knowledge
58 Th e ETN operates as an offi cial intergovernmental organisation promoting mutual cooperation and information exchange on issues related to organ (and tissue) donation and transplantation, which is seen as particularly important given members' diff ering levels of infrastructural development of organ procurement and transplantation. Th e European Organ Exchange Organizations (EOEO) was also established in 2004 and brings together national and supranational organ procurement and exchange organisations that operate in Europe. Th e EOEO focuses on developing standards for quality, safety and traceability involved in the procurement and exchange of organs for transplantation. 
Improving Quality and Safety
Th e fi nal two Priority Actions in the Commission's action plan aim to address the third main challenge of improving quality and safety. Priority Action 10 focuses on developing a methodology that provide the basis for establishing a common accreditation system for organ donation/procurement and transplantation programmes. 61 Such system would feed into an EU-wide regulatory regime in the fi eld, which will be discussed in more detail in the next section of the paper. Priority Action 9 is focused on developing a common approach to the evaluation of post-transplant results which will be supported by the creation of (a network of ) registers to provide follow-up information on the health and well-being of organ recipients. In addition, there are plans to develop a common approach to determining what constitutes an acceptable level of risk in relation to the use of what has been described as 'expanded' or 'marginal' donors. Th e expectation of the Commission is that such activities will lead to the development of best (medical) practices in these areas.
Th e development of a common EU-wide approach to evaluating post-transplant results involving organ recipients is to be welcomed, particularly in relation to follow-up on the health of recipients at regular time intervals following transplantation. 62 Th is may also help to identify the extent to which re-transplantation becomes necessary, as well as examining post-transplant outcomes resulting from the broadening of categories of donation, including expanded criteria donation (ECD) and non-heart-beating donation (NHBD). 63 Although it has been argued that the use of these types of organs should be considered only in exceptional cases, 64 there has been growing support by those working in transplant medicine for the increased use of ECD organs in recent years. It is recognised in the EU 60) For further details, see http://www.ceapir.org/wb/pages/ceapir/activities/epat.php. 61) Commission of the European Communities. Communication, 8.12.2008, supra, n. 2, 8, 12-13. 62) Ibid., 7, 12. 63) Th e other term that is commonly used to describe this category is donation after cardiac death. 64) It has been suggested that the use of ECD organs should only be contemplated in exceptional cases, in the context of the individual doctor and patient relationship, see Roscam Abbing, supra, n. 34, 65-66. context, however, that further work is needed on defi nitions, specifi c categories as well as follow-up on recipients who receive such organs. 65 In recent years, for example, ECD organs have been used from deceased donors who were over the age of sixty years. In the case of kidney transplants, ECD organs have been used where there has been a history of hypertension or where stroke was the cause of death. Other instances involving the use of ECD organs have included those where the donor was infected with Hepatitis B and where the donor had a history of cancer. In accepting the use of ECD organs, it has been recognised that the outcomes achieved by recipients post-transplant are likely to be less successful than those where a standard compatibility match was achieved as between donor and recipient. 66 Given that a potential recipient with end-stage renal failure may be facing imminent death, however, it has been argued that even given the prospect of a less than optimum outcome, ECD organs need to be considered where they may represent a life-saving option, at least in the short to medium term. In the circumstances, transplant clinicians have focused on reducing as much as possible the diff erences in outcome between standard and ECD organ donation post-transplant. 67 Although NHBD is sometimes included in the ECD category, it is considered separately for present purposes given the particular ethical and legal problems it is likely to raise within the EU context. NHBD occurs where there is a diagnosis of death based on cardiopulmonary rather than neurological criteria (e.g. brain stem death), the latter diagnosis having achieved widespread ethical and legal acceptance as being necessary before deceased organ donation can take place. 68 Th e vast majority of Member States (86%) currently provide a statutory defi nition of brain stem death, with three Member States providing guidelines. Th e criteria used to establish brain stem death, however, vary widely as between Member States.
For example, the number of doctors required to diagnosis brain death ranges between two and four in Member States. 69 Th is variability with regard to the diagnosis of death is also said to contribute to the failure to promote NHBD as a category of potential organ donation. 70 Further complications arise because only 45% of Member States have legislation and/or guidelines in place with respect to the defi nition and/or use of NHBD. 71 Th is is so notwithstanding the development of the Maastricht criteria which elaborated on controlled and uncontrolled NHBD. 72 Even with the publication of such criteria, however, ethical concerns remain among experts and other stakeholders over the diagnosis of death based on cardiopulmonary, rather than neurological, criteria. 
Th e Proposed Organs Directive
Initial Consultation and Feedback
When the Commission published its initial Communication in May 2007
, it adopted a cautious note about the appropriateness of adopting a framework Directive in the fi eld. Th e Commission acknowledged that the risk-benefi t ratio in the case of organ donation and transplantation was fundamentally diff erent to that involving other human material, such as blood and tissue, and this would need to be taken into account in drafting any proposal for a Directive. Having adopted such a cautionary note, however, the Commission went on to conclude that 'an appropriate and fl exible' EU-wide regulatory regime was possible which would establish a 'basic quality and safety framework'. It intimated that it intended to follow a similar format to the one adopted in the earlier Blood and Tissues and Cells Directives, albeit with some changes to take account of specifi c issues aff ecting organ donation and transplantation. 74 It was clear, however, that the Commission viewed the adoption of a Directive in the fi eld as something that would take place in the short term, rather than the long term.
Th ere was a mixed reaction amongst EU and national institutions, as well as stakeholders and experts, to the Commission's plans to bring forward a framework Directive in the fi eld. While there was general agreement that quality and safety issues were important in the context of organ donation and transplantation, concerns were expressed that as things stood, the proposed quality and safety framework to be included in any proposed Directive was likely to be too stringent and would therefore impose an unwanted administrative burden at national level. With this in mind, national experts urged the Commission 'not to create obstacles which would decrease transplantation activity'.
75 Th e concerns expressed by experts in relation to the proposed Directive were also echoed in the report of the UK House of Lords European Union Committee. Th e Committee took note of the likely adverse consequences at national level that might result from the 'gold-plating' of regulation at EU level. It recommended that the adoption of an EU-wide regulatory regime in the fi eld should remain fl exible, in particular that it should not interfere with the application of expert clinical judgement and informed patient choice. 
Overview of the Proposed Organs Directive
In publishing its proposal for a proposed Organs Directive, the Commission has clearly attempted to take on board feedback received about the potential adverse consequences that could result from a rigid, prescriptive approach to risk regulation. At the time of its publication, the Commission suggested that its proposal should be viewed as complementary to the revised action plan, supporting and triggering the implementation of priority actions. It argued that the proposed Organs Directive aimed at setting minimum standards in relation to key aspects of organ donation and transplantation, without being too prescriptive. In adopting this approach, the Commission further argued that it would provide for suffi cient fl exibility on the part of Member States to adapt their existing national systems to the requirements of the new regulatory regime without too much 'red tape and administrative burden'. 77 An examination of the proposed Organs Directive shows similarities, as well as diff erences, from earlier Blood and Tissues and Cells Directives that were adopted pursuant to the same competence.
78 Th e earlier two Directives included standardsetting for quality and safety in a range of quality and safety in relation to various steps in the donor-recipient chain. 79 Taking account of necessary diff erences due to the specifi cities of human organ donation and transplantation, this is also followed to some extent in the proposed Organs Directive with standard-setting for quality and safety in relation to the donation, procurement, testing, characterisation, preservation, transport and transplantation.
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Th e proposed Directive is divided into a number of chapters: subject matter, scope and defi nitions (Chapter I); the quality and safety of organs (Chapter II); donor and recipient protection (Chapter III); obligations of the competent authorities and exchanges of information (Chapter IV); exchanges of organs with third countries and European organ exchange organisations (Chapter V); general and fi nal provisions (Chapters VI and VII). In the following sections, I examine key aspects of the proposed Directive, rather than attempting to cover each Article or Chapter in detail. It is also important to keep in mind that it is an examination of provisions of a proposed Directive in the fi eld, and not an adopted text. Although the broad outline of key provisions in the proposal are likely to remain in the adopted text, there will no doubt be a range of amendment before the fi nal text is agreed. Th erefore, the examination of key aspects of the proposed Directive in the following sections needs to be viewed with this note of caution in mind.
A Regulatory Framework for Basic Quality and Safety Requirements
In the Explanatory Memorandum to the proposed Organs Directive, the Commission makes clear that the aim is to establish basic quality and safety requirements needed in every transplant system. 81 One of the key provisions in this regard is the requirement that national quality programmes be established in line with 'standard operating procedures' across a range of specifi c areas. 82 Th is term recurs on a regular basis throughout the proposed Directive. While it was used on occasion in the earlier Blood and Tissues and Cells Directives, 83 it is defi ned for the fi rst time in the proposed Organs Directive. It appears to allow for some degree of fl exibility on the part of Member States in relation to meeting their obligations with respect to aspects of national quality programmes in areas such as verifi cation procedures to be used for donor identity and donor consent, characterisation of donor organs, traceability of organs, the reporting of adverse events and the recall of organs.
84 Th e importance for quality and safety purposes of an appropriate characterisation of organs is also emphasised with requirements as to provision of information, testing and assessment by a qualifi ed laboratory.
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As was made clear in the Commission's action plan, organisational arrangements are seen as crucial for enhancing organ availability and therefore addressing the problem of chronic organ shortage at national level. To this end, Member States are required to identify the organisational structure and operational procedures of their organ procurement organisations, including job descriptions, accountability and reporting relationships. Key aspects of the organ procurement are also required to be put in place, including the circumstances in which donor selection takes place, the use of dedicated facilities, as well as the use of appropriate personnel and operating theatres and equipment. 86 Overseeing the authorisation of such organisations, as well as ensuring that they meet the required quality and safety standards will be the responsibility of the designated competent authority in individual Member States. 
Th e Protection of Donors and Recipients
Key aspects of donor and recipient protection are dealt with in Chapter III of the proposed Directive. Th ere are specifi c provisions relating to the protection of living organ donors which require that all necessary information be provided so as to enable them to make an informed decision about whether or not to donate. Selection requirements for living organ donation include an assessment by qualifi ed healthcare professionals regarding their health and medical history, as well as a psychological evaluation if necessary. It also provides for the exclusion of organ donation by living donors on the grounds that the donation may present a (serious) health risk to potential recipients or themselves, particularly in the context of transmitting disease. 88 Interestingly, no reference is made as to any specifi c limits or exclusions will be placed on the type of living organ donors based on their relationship (spousal, genetic, unrelated) to potential organ recipients. As previously discussed in this paper, this issue and the potential ethical conundrums it raises are clearly a matter of concern for the Council of Europe, as well as a range of other commentators. It will therefore be interesting to see whether or not amendments will be made to this Article as a result of inter-institutional negotiations over the fi nal text of the Directive.
In addition, Chapter III also contains requirements concerning the protection of data collected on donors and recipients. Although it is recognised in the Commission's action plan that the collection of data on organ donation processes and 85) Article 7 and Annex, proposed Organs Directive. 86) Arts. 5-6, proposed Organs Directive. 87) For further details of the work to be done by the designated competent authorities in Member States, see Arts. 18-20, proposed Organs Directive. 88) Article 15, proposed Organs Directive. transplant outcomes is important for the purposes of facilitating further advances in transplant research and medicine, the proposed Directive also recognises the importance of protecting any personal data in line with relevant EU legislation, 89 as well as ensuring that all such data collected is anonymised, so as to prevent identifi cation of donors and recipients. 90 As EU-wide registries containing such data develop over time, it will be important for bodies such as the Commission to ensure that compliance with data protection legislation is in fact taking place. No doubt this can be facilitated through the provision of regular reporting on the part of Member States and the Commission on the implementation, which is likely to be included as a requirement in the adopted Directive.
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Principles governing organ donation include that both living and deceased organ donation should be voluntary and unpaid; that no fi nancial gain or comparable advantage should be obtained from organ donation; and that the procurement of organs should be carried out on a non-profi t basis.
92 Th e promotion of altruism in organ donation and the prohibition on fi nancial gain from such donation, is linked to broader ethical and human rights' principles regarding the need to uphold human dignity, as well as the need to prevent the instrumentalisation and/or commodifi cation of human beings. Such principles derive normative legal support in the EU's Charter of Fundamental Rights 93 and the Convention on Human Rights and Biomedicine, 94 as well as in its Additional Protocol on the transplantation of human organs and tissue. 95 While conceding the normative and legal force of these principles governing organ donation, a question needs to be raised as to whether such principles should provide the only basis on which organ donation should take place within the EU. Th e promotion of altruistic, non-remunerated organ donation has failed to address the growing shortage of organs and this persisting shortage results in thousands of individuals dying each year whilst on waiting lists. Th is ongoing human tragedy necessitates a more detailed examination of whether, and if so what, principled alternatives to altruistic, non-remunerated organ donation should be considered. Th ere is a wealth of academic and policy literature published which examine alternative approaches to increasing the rate of organ donation, including permitting the sale of organs; 96 establishing diff erent types of markets to facilitate payment for organs; 97 and incentivising organ donation through a range of fi nancial measures. 98 While it is outside the scope of this paper to examine the merits (or otherwise) of these various positions on organ donation, it is disappointing in my view that the Commission chose not to examine the diverse range of opinions and commentary on such alternative approaches, given the current problems engendered by chronic organ shortage.
99
In relation to regulatory requirements covering consent to organ donation, the EU's competence to act on this issue is circumscribed by Article 168(7) TFEU, which states that national provisions regarding the donation or medical use of organs shall not be aff ected by the adoption of minimum harmonisation measures under Article 168(4)(a) TFEU. Th is limitation accounts for the reference in the proposed Organs Directive to the requirement that 'procurement shall only be carried out after compliance with all mandatory consent or authorisation requirements in force in the Member State concerned'. 100 As the Commission makes clear in its supporting policy documentation, there is a degree of variation as between Member States in relation to the consent regimes that have been adopted in relation to deceased organ donation, refl ecting the national specifi cities of historical, socio-cultural and medical contexts.
101 Th e desire on the part of Member States to ensure protection and political fl exibility with respect to national approaches on consent was no doubt a key factor in relation to the inclusion of the limitation in Article 168(7) TFEU. Two types of consent regimes predominate in the EU context: an opt-in system which requires explicit consent from donors (e.g. donor card, donor registry) prior to death that they consent to organ donation; and an opt-out system where consent is presumed because donors do not object to organ donation during their lifetime, in circumstances where there are usually national guidelines and/or laws in place setting out how such objections can be made. Th is latter type of regime is more commonly referred to as one based on presumed consent. Th ere are soft and hard variations of the scheme that have been adopted in relation to these two types of schemes. In the case of soft presumed consent regimes, it is still usual to consult with and/or seek the consent of families before organ donation involving their deceased family member takes place.
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Variations in consent regimes have also led to a lively debate in the academic and policy literature regarding what type of regime is likely to result in an increase in the rate of deceased organ donation. On the one hand, there are those who argue that a presumed consent regime is to be preferred, pointing to empirical research which shows a correlation between presumed consent regimes and higher rates of organ donation. 103 Others challenge this argument, arguing that it is the organisational arrangements that are put in place with regard to organ procurement that are most likely to bring about higher rates of organ donation, and not the presumed consent regime on its own. 104 Th is issue was recently the subject of national political debate in the UK with calls at senior government level for the introduction of a presumed consent regime as off ering the best way forward for increasing the rate of deceased organ donation. 105 Following further consideration of the issue, however, the government's key advisory body found that there was no convincing evidence that a change to a presumed consent regime would result in a signifi cant increase in the rate of deceased organ donation in the UK. In the circumstances, it recommended that there be no change to the UK's current opt-in regime and that eff ort instead be focussed on improving organisational arrangements with respect to organ procurement. Th is approach was 102) S., Gevers, A. Janssen, and R. As previously discussed in this paper, a range of regional cross-border organisations and arrangements already exist within Europe. It is to be hoped that the adoption of the Directive will facilitate not only greater cross-border exchange of organs where appropriate, but that the Commission takes the lead in ensuring that the allocation criteria for cross-border organ exchange is fair, just and transparent.
Adding Value? Matters for Concern
Th e Commission's current action plan on organ donation and transplantation is laudable in its aim, and ambitious with regard to its objectives. In relation to some of the priority actions, however, there are indications that it is likely to be too ambitious to achieve within the stated six-year lifespan of the action plan. Th e minutes of the experts' meeting held following the publication of the action plan revealed a narrowing of focus with regard to work to be done on priority actions, with the creation of a technical working group on increasing the rate of deceased organ donation, but the postponement of work on living organ donation for a further two years. Th ere also appears to be little current interest on the part of experts in promoting a European awareness-raising campaign on organ donation, nor in taking any immediate action on issues related to organ traffi cking. Concerns were also expressed that there was a risk of duplication of work already done by the Council of Europe in relation to establishing a common set of indicators and a methodology to monitor and evaluate organ donation and transplantation policy at national level. In response to such concerns, Commission staff claimed that this would not arise, as the work to be done in this area would be based on the fi ndings from two EU funded projects in the area.
109
Th e minutes of this recent experts' meeting raise a number of concerns about aspects of EU governance in organ donation and transplantation. First, it would be benefi cial if the Commission could clarify exactly how it intends to make use of existing pan-European expertise in the fi eld. Th is should be done in order to avoid the problem of duplication of eff ort resulting from work already done, particularly by experts working under the auspices of the Council of Europe. As has been previously discussed in this paper, EU governance in the fi eld has not emerged in a pan-European vacuum. An existing 'epistemic community' of experts in organ donation and transplantation already exists who have long engaged in information-sharing and cross-national policy learning. 110 Given limited national resources and personnel, it is incumbent on the Commission to draw on this body of knowledge and expertise in relation to the work to be done under its action plan.
Th e question of how the Commission proposes to integrate existing panEuropean expertise in the fi eld also raises a broader point about the role of experts in emerging EU governance in the fi eld of organ donation and transplantation. Most pan-European activity to date in the fi eld has been driven through informal, non-legally binding arrangements devised by experts, operating in a largely technocratic environment. Th is is likely to change with greater EU involvement and activity in the fi eld. Th ere is likely to be a shift of power and infl uence away from such experts towards Member States, their political and institutional representatives and EU institutions, such as the Commission. In addition, the emerging EU policy community in organ donation and transplantation is likely to involve a wider array of actors and organised interests with potential to infl uence politics and policy-making processes in the fi eld, than was previously seen at European level. Th e dynamics of policy-making in a multi-level governance environment is such that national experts will be one, albeit highly infl uential, group amongst a number of other stakeholder groups seeking to infl uence EU policy in the fi eld. Having said that, their prominence is likely to be assured in the long term given that their input is essential for the drafting and implementation of technical aspects involved in policy and regulatory initiatives in the fi eld. Th e timetable for the adoption of the Organs Directive, as well as its transposition into national law, is also a matter of concern. Given the ambitious objectives of the Commission's action plan, diff ering levels of infrastructural development regarding organ procurement in Member States, and questions regarding additional administrative burden at national level, it is unclear how an Organs Directive is likely to add value in the short term. Although the Commission claims that a Directive would simply incentivise work already being done under the action plan and would therefore be unlikely to add to the administrative burden at national level, it is not clear that this will be the case. Unlike the action plan, a Directive carries legally-binding obligations, which are required to be met within a specifi ed time-frame. As has become apparent in relation to the Blood and Tissues and Cells Directives, substantial transaction costs and other unintended consequences were incurred in relation to their implementation at national level, particularly in the case of new accession Member States. 111 As it stands, the broad framework of the proposed Organs Directive is such that much work still needs to be done by Member States in relation to fl eshing out aspects of the quality and safety framework. Th is begs the question as to whether this would be better done under the work programme set out under the action plan. Subject to review at regular intervals, a decision could then be taken to adopt an Organs Directive once key aspects of the work programme are completed, particularly with regard to embedding eff ective organisational arrangements involving organ procurement at national level.
Another matter for concern is whether and, if so, how the Commission should deal with ethical issues in organ donation and transplantation that may give rise to confl ict between experts, stakeholders and/or other EU institutions. On the one hand, it could be argued that ethical issues in the fi eld are a matter for Member States, and that EU competence in the fi eld is limited to undertaking activities designed to strengthen cooperation between Member States, as well as adopting minimum harmonisation measures involving standard setting for quality and safety. On the other hand, there are a range of ethical issues raised by aspects of organ donation and transplantation, such as living organ donation, the use of ECD organs, and organ allocation criteria to name but a few discussed in this paper, which should be taken into consideration in transplant medicine, as well as in the degree of legal protection that should be provided to both donors and recipients, in the EU context. Indeed, the evidence from the fraught inter-institutional negotiations that took place in relation to the earlier Blood and Tissues and Cells Directives revealed the diffi culties of attempting to separate out ethical issues from those related to risk in relation to the use of human material. While political compromises were 9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  391 achieved in both cases which enabled the adoption of the Directives, the failure to engage more fully with ethical concerns raised during the course of such negotiations was not a situation that was unlikely to engender public trust or confidence in the legitimacy of policy and regulatory processes in what is acknowledged to be a politically-sensitive area of governance at EU level.
112 It would therefore be benefi cial if the Commission clarifi ed it proposes to deal with ethical aspects raised by transplant medicine and research and how this will in turn will feed into a principled approach to technical and regulatory processes associated with governance initiatives in the fi eld.
What the negotiations over the fi nal texts of the Blood and Tissues and Cells Directives also revealed was the problems created by having such a limited competence to act in relation to the governance issues that are raised by the use of human material. Th e political impetus for the creation of the competence originated in the political fall-out from HIV/AIDS blood contamination scandals at national level. 113 In this context, the transfer of a limited competence to enable minimum harmonisation measures to be taken which established an EU-wide risk regulation regime to enhance blood safety made sense. Th e diffi culties engendered by such a narrowly-circumscribed competence, however, became apparent in the case of the Tissues and Cells Directive and are perhaps even more so in the case of the proposed Organs Directive.
114 A more diff erentiated approach to risk management is needed in this instance, given the chronic shortage of organs in most Member States and the fact that organ transplant represents the only lifesaving option for many patients. In the circumstances, a regulatory regime is needed that remains suffi ciently fl exible to allow for discretion in the exercise of clinical judgement and patient choice with regard to determining the acceptability of risks relating to organs which become available for transplantation. Th e Commission has sought to accommodate such diffi culties by promoting a hybrid approach to EU governance in the fi eld, combining new governance mechanisms, such as OMC, as well as more traditional command and control measures, such as those provided for under Article 168(4)(a) TFEU.
115 Whether this will approach to governance will work effi ciently and eff ectively in practice, however, remains to be seen.
Conclusion
Th is article examined recent developments in EU governance of organ donation and transplantation, in particular the Commission's current action plan and the proposed Organs Directive. Such examination revealed that while there is much potential for value-added action in the fi eld at EU level, a number of concerns remain. Th e action plan is ambitious and it is unclear whether the current timescale for meeting the main challenges set out in the plan is realistic, given the scope of the planned work programme, diff ering levels of organisational development of organ procurement at national level, and concerns over the extent to which additional administrative burdens will be imposed by EU action given limited national resources in the fi eld. In addition, it would be benefi cial if the Commission clarifi ed in its published policy documentation how it proposes to build upon existing pan-European expertise in transplant research and medicine, as well as how it proposes to deal with problematic ethical issues which are likely to arise in the fi eld. While a Directive is to be welcomed in terms of establishing a basic quality and safety framework, it is not clear that there is merit in its adoption and implementation in the short-term, given the demands imposed at national level by the work programme set out in the action plan. Th e adoption of a Directive creates legal obligations with regard to its transposition into national law and it may impose signifi cant transaction costs and raise particular resource diffi culties for a number of Member States. Time and eff ort could perhaps more effi ciently and eff ectively be spent in the short term on achieving priority actions in the action plan, particularly those relating to establishing optimum national organisational arrangements with regard to organ procurement. Overall, EU action on organ donation and transplantation should be viewed as a welcome development. Ultimately, the added value of its governance initiatives in the fi eld is likely to be measured by the extent to which they successfully address the ongoing problem of organ shortage in Member States.
